A team led by Peter Schultz, Scripps Family Chair Professor and member of the Skaggs Institute for Chemical Biology at The Scripps Research Institute, has been awarded a $4.3 million grant from the California Institute for Regenerative Medicine (CIRM) to research stem-cell-based therapies to treat multiple sclerosis.
Because stem cells can change or differentiate into many different cell types (such as nerve cells, muscle cells, and skin cells), they hold the life-changing medical potential to provide a source of cells to replace those permanently lost by a patient.
The Scripps Research project focuses on restoring the myelin sheath—a protective covering that
Image via Wikipedia
First and foremost, the new international guidelines on stem cells, with four Italians among the authors, need to be clear, eliminating false illusions, incredible exaggerations, and confusion due to excess emphasis placed on the therapeutic properties of adult stem cells compared to embryonic stem cells.
The International Society for Stem Cell Research (ISSCR) has decided to impart some order in a field of research which, for various reasons, is growingly involved in issues that have little to do with research.
“Regulation is necessary,” according to the Society, commenting about studies that risk creating exaggerated controversy or omitting risks regarding
Scientists sporting white coats and safety gloves are working in a bright Food and Drug Administration (FDA) lab on an incredible project.
They are part of FDA’s MSC Consortium, a large team of FDA scientists studying adult mesenchymal stem cells (MSCs)—cells that could eventually be used to repair, replace, restore or regenerate cells in the body, including those needed for heart and bone repair.
The scientists’ investigational work is unprecedented: Seven labs at FDA’s Center for Biologics Evaluation and Research formed the consortium to fill in gaps in knowledge about how stem cells function (…)
It may seem surprising, but more than 1,700 dogs in the USA with arthritis have already been treated with their own stem cells.
Remember the saying “Patient Heal Thyself?” We all — human and animals — carry around a stem cell repair kit that is used every day in helping heal the minor bumps, bruises, cuts and more serious injuries.
These stem cells are called “adult” stem cells and are found throughout the body. They sit there waiting for the signal that they are needed and they rush to the scene of the injury and begin the healing process.
So we really
Researchers and using stem cells as tools for disease study, drug screening, clinical trial strategy, and personalized medicine. The induced Pluripotent Stem cell (iPS) is giving us a chance to rethink the way we are developing new drugs. These iPS cells are usually created from somatic cells (such as skin), and not embryos or adult stem cells. In creating iPS from patients’ diseased cells, scientists can study the disease in vitro, looking for disease phenotypes, applying microenvironmental stress, and testing new drugs. Compared to animal model testing (e.g. mice), this represents a significant breakthrough, that can be used to